Infermedica Raises $10M in Series A Funding


Infermedica, a Wrocław, Poland-based AI health tech startup, raised $10m in Series A funding.

The round, which brought total funding to date to $15m, was led by EBRD and Heal Capital with participation from existing investors Karma Ventures, Inovo Venture Partners, and Dreamit Ventures.

The investment will be used for platform R&D to further enhance patient triage and symptom checking features as well as clinical decision support analysis – including intake collection, differential diagnostics and lab test interpretation – and to expand operations in Germany and the US, where Infermedica currently has one office.

Founded in 2012 in by Piotr Orzechowski (CEO), Infermedica provides an AI-driven platform for insurance, telemedicine companies, and health systems to increase efficiency through fast, digital symptom-checks. The platform’s available interfaces include:

  • Symptom Checker – a white-label, customisable application that provides fast digital symptom checking and analysis, suggesting a list of the most likely conditions. Symptom Checker is available as a chatbot and voice assistant.
  • Call Centre Triage – a solution that aids telemedicine personnel to pre-diagnose patients and understand condition severity so they can provide relevant healthcare instructions. Call Centre Triage prevents unnecessary urgent care visits, and detects urgent cases quickly.
  • Infermedica API – direct access to the engine through a fully-customisable API that can be integrated directly onto clients’ websites, apps or telehealth systems.

The company has nearly 60 B2B clients in the healthcare space, spanning 30 countries and has completed more than 6 million patient health checks. The platform has nearly 60 B2B partners across 30 countries, including Microsoft, Allianz, Global Excel, Sana Kliniken, and Médis, and has performed more than 6 million health checks globally.

Infermedica currently employs more than 100 specialists – including doctors, data scientists, and engineers.



Join the discussion